Prospective Post Marketing Surveillance to Evaluate the Safety and Efficacy of Etanercept Under Usual Care Settings in Patients With Psoriatic Arthritis (PsA) Treated by Rheumatologists

Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

Change From Baseline in Patient Assessment of Itching at Week 52

Change From Baseline in Percent Body Surface Area (BSA) Affected by Psoriasis at Week 52

Change From Baseline in Disease Activity Score Based on 28 Joints Count (DAS 28) at Week 52

Change From Baseline in Ritchie Index at Week 52

Change From Baseline in Physician Global Assessment of Disease Activity at Week 52

Number of Participants With Nail Involvement

Change From Baseline in C-reactive Protein (CRP) at Week 52

Change From Baseline in Patient Assessment of Pain at Week 52

Change From Baseline in 12-Item Short Form Health Survey (SF-12) at Week 52